JPMorgan lowered the firm’s price target on Evolent Health (EVH) to $7 from $13 and keeps an Overweight rating on the shares. The firm updated the company’s model.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health price target lowered to $9 from $16 at Canaccord
- Evolent Health: Strong Growth Prospects and Strategic Market Positioning Justify Buy Rating
- Evolent Health: Positioned for Growth with Strong Fundamentals and Valuation Upside
- Evolent Health upgraded to Overweight at Stephens with sentiment near bottom
- Evolent Health upgraded to Overweight from Equal Weight at Stephens